Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
Found 85 records
$229,544.00
Apr 14, 2021
Academia
Identifying subgroups of COVID patients that are more likely to require specific therapies, tertiary level care or who are safe to be discharged home with minimal monitoring will significantly improve the ability to plan and prepare while preserving resources when individuals are unlikely to have severe disease.
$259,257.00
Apr 14, 2021
Academia
Identifying subgroups of COVID patients that are more likely to require specific therapies, tertiary level care or who are safe to be discharged home with minimal monitoring will significantly improve the ability to plan and prepare while preserving resources when individuals are unlikely to have severe disease.
$750,000.00
Apr 1, 2021
Not-for-profit organization or charity
Exploiting genome editing technology to engineer enhanced and novel therapeutic attributes into clinically relevant cell types represents a disruptive modality to circumvent current challenges in cell- and gene-based therapies. The goal of this Project is to establish genome engineering tools amenable to automated and high throughput platforms that facilitate the engineering of therapeutic attributes into human induced pluripotent stem cells (iPSCs). Once established, these tools will be foundational to accelerating the innovation and discovery cycles of engineered cell-based therapies with increased safety, affordability and accessibility in the space of regenerative medicine and immunotherapy.
$1,000,000.00
Apr 1, 2021
Not-for-profit organization or charity
This Project aims at establishing a current Good Manufacturing Practices (cGMP)-compliant platform to manufacture clinical grade lentiviral vectors (including production, purification and quality control) at the Centre of Excellence for Cellular Therapy (CETC) of Hôpital Maisonneuve-Rosemont. It builds on the capacity of the CETC, the only fully operational cGMP-compliant cell therapy facility in Canada, to generate viral vectors of clinical and commercial grade at the 50L scale.
$198,000.00
Mar 29, 2021
Not-for-profit organization or charity
Yet, clinical application of stem cell therapies for muscle degenerative diseases has been limited due in part to the complexities of manipulating or augmenting stem cell systems in vivo. Designing optimal stem cell therapies is therefore extremely challenging because testing of every design is highly time-consuming and costly.
$221,364.00
Jan 1, 2021
Academia
Potent and specific gene therapies used to treat patients have been limited by the lack of delivery vehicles to introduce them into specific cells.
$195,000.00
Dec 22, 2020
Academia
These efforts are expected to help evaluate the functions of genes/proteins from selected Acinetobacter baumannii lytic phages, for potential therapy as alternatives to antibiotics.
$96,800.00
Sep 24, 2020
Academia
DNA aptamers, small sequences of single-stranded DNA, may be used for biological sensing, cell therapies, immunotherapy, alternatives to antibodies in therapies, etc.
$96,800.00
Sep 24, 2020
Academia
DNA aptamers, small sequences of single-stranded DNA, may be used for biological sensing, cell therapies, immunotherapy, alternatives to antibodies in therapies, etc.
$100,000.00
Sep 17, 2020
Academia
This Project seeks to produce recombinant St1Cas9 and variants and test their efficiency both in vitro and in vivo. These recombinant gene editing tools will become part of the toolkit the NRC-CGT Program aims to build to facilitate multiplex combinatorial gene editing in induced pluripotent stem cells (iPSCs) and immune cells. Along with the production of SpCas9, MAD7, and potentially Cas12a, the production of St1Cas9 and variants will broaden target flexibility and help to accelerate innovation and discovery cycles in engineered cell and gene therapies.